Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18573453 | 0.93 | RAB9A (0.60) | HDAC6RAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL18573588 | 0.84 | HDAC6 (0.58) | HDAC6RAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL6246675 | 0.80 | HDAC6 (0.72) | HDAC6RAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL18573578 | 0.80 | HDAC3 (0.53) | HDAC6RAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL18573537 | 0.79 | NPC1 (0.63) | HDAC6RAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL23091249 | 0.78 | SNCA (0.53) | RAB9ANPC1SMN1; SMN2KMT2AHPGDS | |
| SCHEMBL18573590 | 0.77 | NPC1 (0.62) | HDAC6RAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL23091268 | 0.76 | KDM4E (0.50) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3098138 | 0.76 | HDAC6 (1.00) | HDAC6HDAC1MAPTTP53 | |
| SCHEMBL23091267 | 0.76 | PTPN11 (0.55) | HDAC6RAB9ANPC1SMN1; SMN2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3339299-B1 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | AUTOPHAGYSCIENCES INC (KR) | 2021-03-03 | — | — | EP | claimed |
| US-20200255397-A1 | METHOD FOR TREATING LIVER DISEASE BY ADMINISTERING PHARMACEUTICAL COMPOSITION COMPRISING CATECHOL DERIVATIVE | Autophagysciences Inc. (KR) | 2020-08-13 | — | — | US | claimed |
| US-10662169-B2 | Catechol derivative and pharmaceutical composition comprising the same | Autophagysciences Inc. (KR) | 2020-05-26 | — | — | US | claimed |
| US-20180244644-A1 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Autophagysciences Inc. (KR) | 2018-08-30 | — | — | US | claimed |
| EP-3339299-A2 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Autophagysciences, Inc (KR) | 2018-06-27 | — | — | EP | claimed |
| EP-3339299-B1 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | AUTOPHAGYSCIENCES INC (KR) | 2021-03-03 | — | — | EP | disclosed |
| EP-3339299-B1 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | AUTOPHAGYSCIENCES INC (KR) | 2021-03-03 | — | — | EP | disclosed |
| CN-107922374-B | Novel catechol derivatives and pharmaceutical compositions containing the same | 自体吞噬科学有限公司 | 2020-11-06 | — | — | CN | disclosed |
| US-20200255397-A1 | METHOD FOR TREATING LIVER DISEASE BY ADMINISTERING PHARMACEUTICAL COMPOSITION COMPRISING CATECHOL DERIVATIVE | Autophagysciences Inc. (KR) | 2020-08-13 | — | — | US | disclosed |
| US-20200255397-A1 | METHOD FOR TREATING LIVER DISEASE BY ADMINISTERING PHARMACEUTICAL COMPOSITION COMPRISING CATECHOL DERIVATIVE | Autophagysciences Inc. (KR) | 2020-08-13 | — | — | US | disclosed |
| US-10662169-B2 | Catechol derivative and pharmaceutical composition comprising the same | Autophagysciences Inc. (KR) | 2020-05-26 | — | — | US | disclosed |
| US-10662169-B2 | Catechol derivative and pharmaceutical composition comprising the same | Autophagysciences Inc. (KR) | 2020-05-26 | — | — | US | disclosed |
| US-20180244644-A1 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Autophagysciences Inc. (KR) | 2018-08-30 | — | — | US | disclosed |
| EP-3339299-A2 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Autophagysciences, Inc (KR) | 2018-06-27 | — | — | EP | disclosed |
| EP-3339299-A2 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Autophagysciences, Inc (KR) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017034242-A2 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 유영제약 | 2017-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255397-A1 | METHOD FOR TREATING LIVER DISEASE BY ADMINISTERING PHARMACEUTICAL COMPOSITION COMPRISING CATECHOL DERIVATIVE | ATG7, BECN1, SLC10A1 | HDAC6 233/4885RAB9A 167/4885NPC1 27/4885 |
| US-10662169-B2 | Catechol derivative and pharmaceutical composition comprising the same | BECN1, ATG7, SQSTM1 | HDAC6 213/4885RAB9A 197/4885NPC1 45/4885 |
| US-20180244644-A1 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | BECN1, ATG7, TFEB | HDAC6 136/4885RAB9A 122/4885NPC1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.